Evotec

Evotec will use Merck's collection of genetic reagents — including viral CRISPR and shRNA libraries — in target discovery programs.

Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification.

NEW YORK (GenomeWeb News) – Evotec said today that the CHDI Foundation has extended and expanded the two parties' collaboration on Huntington's disease research through 2017.

NEW YORK (GenomeWeb) – Evotec said this week that it has achieved a milestone in its protein biomarker work with Roche, as the drugmaker selected for phase I clinical trial use a response prediction marker developed through the two firms' collaboration.

NEW YORK (GenomeWeb News) – Evotec today said that it has forged an alliance with the Harvard Stem Cell Institute to identify compounds that can prevent or slow down the loss of motor neurons, a characteristic of amyotrophic lateral sclerosis.

While chemical proteomics has traditionally focused on pharmaceutical work, several recent collaborations suggest that the field is establishing a foothold within agricultural research, as well.

NEW YORK (GenomeWeb News) – Evotec and the Jain Foundation today said they have extended and expanded their 2012 research collaboration aimed at dysferlinopathy.
Terms of the expanded deal were not disclosed.

NEW YORK (GenomeWeb News) – Evotec today announced a collaboration to support the development of compounds in development at Dow AgroSciences.

German pharmaceutical firm Evotec said this week that it has entered a research collaboration with Apeiron Biologics in which it will apply its chemical proteomic capabilities to the development of immunomodulatory compounds to treat cancer.

NEW YORK (GenomeWeb News) – Evotec today announced it has acquired custom cell and cell-based reagents firm Cell Culture Service for up to €2.2 million ($2.9 million).

Pages

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.